Latest News & Features
Careers
After almost 20 years at Goodwin, the patent and trade secrets supremo whose clients include Meta, IBM and Novartis, joins his new employer’s Washington, DC office. 8 July 2026
Pharma
Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation. 7 July 2026
Careers
Focusing on technology and life sciences clients, the new San Fran-based Debevoise & Plimpton hire brings both in-house and private practice litigation experience across trade secrets and commercial disputes. 7 July 2026
Europe
The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay. 6 July 2026
Asia
A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models. 3 July 2026
Americas
A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process. 2 July 2026
Careers
The firm has appointed two new partners in Basel and Bristol, adding decades of expertise from the pharmaceutical and biotech sectors to its growing life sciences practice. 2 July 2026
Pharma
Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country. 1 July 2026
Careers
A first-chair trial lawyer with two decades in high-stakes patent and trade secret disputes brings experience across medical devices, biologics, and pharmaceuticals, alongside a broader technology-focused practice. 1 July 2026
Americas
Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market. 30 June 2026